Products
Keliximab Biosimilar Monoclonal Antibody (CD4) for Research
Anti-CD4 therapeutic antibody (Pre-made Keliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Izokibep has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, approximately one eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin. These features lead to the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-881-1mg | 1mg | 3090 |
| GMP-Bios-INN-881-10mg | 10mg | |
| GMP-Bios-INN-881-100mg | 100mg | |
| GMP-Bios-INN-881-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Keliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody |
| INN Name | Keliximab |
| Target | CD4 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - lambda |
| VD LC | IgG1 - lambda |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Biogen, Inc. (Cambridge MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - CD4
1. Protein Tumor necrosis factor receptor superfamily member 13C
2. Gene CD4
3. Organism Homo sapiens (Human)
Function
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. The antigens presented by class II peptides are derived from extracellular proteins while class I peptides are derived from cytosolic proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class II presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of T-helper cells. In other cells such as macrophages or NK cells, plays a role in differentiation/activation, cytokine expression and cell migration in a TCR/LCK-independent pathway. Participates in the development of T-helper cells in the thymus and triggers the differentiation of monocytes into functional mature macrophages.
(Microbial infection) Primary receptor for human immunodeficiency virus-1 (HIV-1) (PubMed:2214026, PubMed:16331979, PubMed:9641677, PubMed:12089508).
Down-regulated by HIV-1 Vpu (PubMed:17346169).
Acts as a receptor for Human Herpes virus 7/HHV-7 (PubMed:7909607).
